Completed PHASE2 INTERVENTIONAL 1-arm NCT00169195

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Gemcitabine-oxaliplatin Plus Rituximab (R-GEMOX) in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma, Non Eligible for High-dose Chemotherapy Followed by Autotransplantation

Sponsor: Eli Lilly and Company

Conditions Diffuse Large Cell Lymphoma

Interventions Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)

Updated 6 times since 2017 Last updated: Sep 1, 2015 Started: Apr 30, 2003 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diffuse Large Cell Lymphoma, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Hoffmann-La Roche
Lymphoma Study Association
Sanofi-Synthelabo

Data source: Lymphoma Study Association

For direct contact, visit the study record on ClinicalTrials.gov .

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials